Patient Preferences for Second-line Type 2 Diabetes Medication Treatment Outcomes


About this study

It is unknown how patient preferences and values impact the comparative effectiveness of second-line medications for Type 2 diabetes (T2D). The purpose of this study is to elicit patient preferences toward various treatment outcomes (e.g., hospitalization, kidney disease) using a participatory ranking exercise, use these rankings to generate individually weighted composite outcomes, and estimate patient-centered treatment effects of four different second-line T2D medications that reflect the patient's value for each outcome. 


Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • ≥ 21 years old.
  • Diagnosis of Type 2 diabetes.
  • Use of ≥ study drug (GLP-1RA, SGLT2i, DPP-4i, SU).

Exclusion Criteria:

  • Insulin use.
  • Cognitive impairment.
  • Terminal or advanced illness.
  • Non-English speaking.
  • Residency in a long-term care setting.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Rozalina McCoy, M.D., M.S.

Open for enrollment

Contact information:

Rozalina McCoy M.D., M.S.

(507) 538-7955

More information


Publications are currently not available

Mayo Clinic Footer